Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-06-08

FDA Approved: ESCITALOPRAM — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for a generic escitalopram oxalate product from Jubilant Cadista Pharmaceuticals Inc., authorizing the continued mar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Escitalopram (escitalopram)

Snippet

SUPPL AP for ESCITALOPRAM (ESCITALOPRAM OXALATE)